Want to join the conversation?
$BMY has nearly 100% coverage for Opdivo in the US. Internationally, Opdivo has now been approved in over 38 countries. In Europe, $BMY has approval for both first and second-line melanoma and squamous lung cancer. Trends in Germany are strong, and $BMY is working through the reimbursement process for most other EU countries.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.